GeoVax Labs (NASDAQ:GOVX) and Rani Therapeutics (NASDAQ:RANI) Head-To-Head Survey
by Sarita Garza · The Markets DailyRani Therapeutics (NASDAQ:RANI – Get Free Report) and GeoVax Labs (NASDAQ:GOVX – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, earnings, profitability, valuation, risk, institutional ownership and dividends.
Earnings and Valuation
This table compares Rani Therapeutics and GeoVax Labs”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Rani Therapeutics | $1.63 million | 51.82 | -$29.67 million | ($0.27) | -2.24 |
| GeoVax Labs | $2.49 million | 0.61 | -$21.47 million | ($11.34) | -0.02 |
GeoVax Labs has higher revenue and earnings than Rani Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings and target prices for Rani Therapeutics and GeoVax Labs, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Rani Therapeutics | 1 | 0 | 4 | 0 | 2.60 |
| GeoVax Labs | 1 | 1 | 1 | 0 | 2.00 |
Rani Therapeutics presently has a consensus price target of $8.33, indicating a potential upside of 1,275.36%. GeoVax Labs has a consensus price target of $150.00, indicating a potential upside of 72,715.53%. Given GeoVax Labs’ higher probable upside, analysts clearly believe GeoVax Labs is more favorable than Rani Therapeutics.
Insider and Institutional Ownership
30.2% of Rani Therapeutics shares are held by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are held by institutional investors. 26.7% of Rani Therapeutics shares are held by insiders. Comparatively, 0.2% of GeoVax Labs shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Rani Therapeutics and GeoVax Labs’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Rani Therapeutics | N/A | -104.60% | -65.17% |
| GeoVax Labs | N/A | -743.64% | -394.74% |
Volatility & Risk
Rani Therapeutics has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. Comparatively, GeoVax Labs has a beta of 3.69, meaning that its share price is 269% more volatile than the S&P 500.
Summary
Rani Therapeutics beats GeoVax Labs on 8 of the 13 factors compared between the two stocks.
About Rani Therapeutics
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
About GeoVax Labs
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.